ClinicalTrials.gg
CompletedNCT06249048Updated Nov 19, 2026

Phase 1/2 Study of Intratumoral Injection of STX-001 in Advanced Solid Tumors as Monotherapy or in Combination With Pembrolizumab

A Phase 1/2 interventional study of STX-001 and Keytruda® in Advanced Solid Tumor, sponsored by Strand Therapeutics Inc.. Completed at 7 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-19.

Primary conditionnone(registry's first term: Triple Negative Breast Neoplasms)Many cancersIs this wrong?The study is open to many cancers (its listed conditions name solid tumors in general), and its title does not single out Triple Negative Breast Neoplasms, so we do not take that as its main condition. It is not compared with other studies by condition.

Sponsored by Strand Therapeutics Inc. · Phase 1/2, Interventional, and Treatment

How we know · 10 judgments

Updated Nov 19, 2026Now CompletedPrimary completion moved+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
39
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Study summary

Phase 1/2, Open-label, Multi-center, First-in-human Study of the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Anti-tumor Activity of STX-001 Delivered by Intratumoral Injection in Patients with Advanced Solid Tumors as a Monotherapy or in Combination with Pembrolizumab. The study now includes a monotherapy cohort targeting visceral lesions and a separate Phase 2 monotherapy cohort for advanced melanoma.

Read the detailed description

This open-label, Phase 1/2, first-in-human (FIH), multiple ascending dose and dose expansion study involves STX-001 administration, alone or in combination with pembrolizumab, to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary antitumor activity in patients with advanced cancers.

Phase 1 consists of 4 planned dose escalation cohorts of STX-001 delivered as a monotherapy (Cohorts 1m), 4 planned dose escalation monotherapy cohorts of STX-001 delivered as a combination therapy with pembrolizumab treatment given concurrently (Cohorts 1c), and an additional monotherapy cohort targeting visceral lesions (Cohort 1vm) that will be evaluated at 30ug, 100ug and 300ug. New patients will be enrolled in each dose escalation cohort.

Phase 2 consists of dose expansion cohorts in patients with 2 defined cancer types: triple-negative breast cancer (TNBC) and melanoma. There will also be a monotherapy cohort for advanced melanoma. Phase 2 will evaluate STX-001 in combination with pembrolizumab; the recommended Phase 2 dose (RP2D) will be selected based on analysis of the totality of data from Phase 1 safety, tolerability, PK, PD and preliminary efficacy data.

02

Conditions studied

  • Advanced Solid Tumor

Browse trials for

Keywords

  • Intratumoral
  • Triple Negative Breast Cancer
  • Melanoma
  • Advance Solid Tumors
  • mRNA
03

In context

Lead sponsor

Strand Therapeutics Inc. is the lead sponsor of 2 studies on the registry; 1 is open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

General Inclusion Criteria:

  • ≥ 18 years of age at the time of screening.
  • Mentally competent and able to understand and sign the form (ICF).
  • (ECOG) performance status of 0 or 1.
  • of ≥ 12 weeks per the Investigator.
  • Body weight ˃ 40 kg.
  • At least 4 weeks from any prior major surgery.
  • Willing and able to provide blood samples prior to the start of this study.
  • Has a tumor lesion amenable to injection, must be accessible for pre and post injection , and the patient must be willing to consent to biopsy, if deemed safe by the Investigator.
  • Laboratory values (Hematology): ≥ 1,000 cells/mm3; count ≥ 75,000 cells/mm3; ≥ 8.0 g/dL.
  • Laboratory values (Renal): Serum creatinine \< 1.5 × (ULN) or ≥ 40 mL/min based on the Cockcroft-Gault estimation
  • Laboratory values (Coagulation): Prothrombin/ (PT/INR) or prothrombin time must be \< 1.5 × ULN;
  • Activated partial thromboplastin time (aPTT) ≤ 1.5 × ULN unless undergoing anticoagulation therapy.
  • Laboratory values (Liver): (AST) and alanine aminotransferase (ALT) \< 2 × ULN; ≤ 2 × ULN or ≤ 5 × ULN for all patients.

Phase 1 Inclusion Criteria:

  • or cytologically documented, locally advanced, or solid tumor.
  • Disease progression confirmed by imaging or other objective evidence after having received standard treatment or patients with solid tumors. Patients must have progressed or are intolerant of at least one .

Phase 2 Inclusion Criteria (TNBC):

  • Histologically or cytologically documented findings consistent with TNBC not amenable to curative surgery, radiation, or other therapy.
  • Prior treatment (for advanced, metastatic or [neo]adjuvant) should have included a taxane and/or anthracycline-based therapy and, where appropriate, an approved .
  • Has disease other than the injected lesion that is measurable by 1.1.

Phase 2 Inclusion Criteria (melanoma):

  • Histologically or cytologically documented findings consistent with advanced melanoma not amenable to curative surgery, radiation, or other therapy. Uveal melanoma is excluded.
  • Patients who are not candidates for or have refused available therapies are also eligible.
  • Received an anti-programmed death-1 (PD-1) / programmed death ligand-1 (PD-L1) inhibitor as monotherapy or in combination with anti-cytotoxic lymphocyte associated protein 4 (CTLA-4) inhibitor and have either primary or secondary checkpoint inhibitor resistance as per Society for Immunotherapy of Cancer (SITC) consensus definition, unless deemed intolerable by the investigator. Patients with BRAF V600E mutant melanoma should have received a BRAF inhibitor as monotherapy or in combination with other targeted agents (mitogen-activated protein kinase [MAPK] kinase [MEK] inhibitors), unless deemed intolerable by the investigator.
  • Has disease other than the injected lesion that is measurable by RECIST 1.1.

Phase 1 and 2 Exclusion Criteria:

  • History of primary immune deficiency.
  • History of disease and/or requiring (except hypothyroidism).
  • History of History of Grade 3 or higher immune-related adverse events. Patient may be enrolled with Medical Monitor approval.
  • History of solid organ transplant and taking immunosuppressive medications.
  • Cardiovascular exclusions: Medical history of an arterial thrombotic event, stroke, or within the past 12 months; medical history of symptomatic congestive heart failure ( classes II-IV) or a cardiac arrhythmia that required treatment within the past 12 months; medical history of myocardial infarction or unstable angina within 6 months before Cycle 1 Day 1; prolongation to > 470 ms in women and > 450 ms in men based on a 12-lead (ECG) in triplicate using the Fridericia formula: QTc = QT / RR1/3.

Recent medical concerns exclusions:

  • Prior direct radiation therapy to the tumor lesion to be injected.
  • Active use of systemic anticoagulants
  • Evidence of active infection requiring intravenous (IV) antibiotics during screening requiring therapy within 7 days prior to Cycle 1 Day 1.
  • Active uncontrolled bleeding, or a bleeding diathesis within 7 days prior to Cycle 1 Day 1.
  • Serious or non-healing wound, fistula, skin ulcer, or non-healing bone fracture within 7 days prior to Cycle 1 Day 1.
  • Known (HIV) infection, active infection, or infection.
  • Virology evaluation should be conducted at screening to include serum HIV antibody, HBc antibody, HBsAg antigen, and HCV antibody. Patients with a positive antibody evaluation for HCV and/or HBc should undergo evaluation to measure HCV RNA or HBV DNA, respectively.
  • Untreated central nervous system tumor, epidural tumor or metastasis, or . Patients with any primary Central Nervous System (CNS) including glioma and current, active, progressing CNS malignancy, including carcinomatosis meningitis are excluded.
  • Patients with treated brain metastases are eligible if there is no evidence of progression for at least 4 weeks after CNS-directed treatment, as ascertained by clinical examination and brain imaging (magnetic resonance imaging [MRI] or computed tomography [CT] scan) during the screening period and off systemic (for at least 2 weeks prior to first dose).
  • Another primary malignancy that has not been treated with curative intent, except for non-metastatic cutaneous basal cell or squamous cell carcinoma, or non-muscle invasive bladder cancer.
  • Serious illness considered by the Investigator as incompatible with participating in this clinical study.
  • Any condition that, in the opinion of the Investigator, would interfere with evaluation of the product or interpretation of the patient's safety or study results.
  • Prior IL-12 therapy.
  • Receipt of any vaccine within 30 days prior to the first dose of study treatment.
  • Use of another anticancer therapy within 3 weeks prior to Cycle 1 Day 1 or 5 half-lives, whichever is shorter.
  • Previously enrolled in this study.
  • Actively enrolled in another clinical study unless it is an observational (noninterventional) clinical study or the follow-up component of an interventional study.
  • Known severe (Grade ≥ 3) to study treatment or any of the of the products.
  • Known psychiatric or substance use disorder that would interfere with the participant's ability to cooperate with the requirements of the study.
  • Currently pregnant (confirmed with positive pregnancy test), breast-feeding or planning to become pregnant within 60 days following treatment. For women of (WOCBP), a negative serum beta-human chorionic gonadotropin (β-HCG) result must be available within a 72 hour window before the first treatment dose.
  • Women of childbearing potential not willing to use a highly effective method of .
  • Unwilling or unable to follow protocol requirements.
Terms in these criteria, in plain language(36)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
39 participants (actual)

Study arms

  • Experimental
    Phase 1 Monotherapy (STX-001)

    A Phase 1, first-in-human (FIH), multiple ascending dose administration of intratumoral STX-001 monotherapy to evaluate safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and preliminary antitumor activity in patients with advanced cancers. Consists of four planned dose-escalation cohorts (Cohorts 1m) plus permitted backfill enrollment (up to 30 patients). New patients are enrolled in each dose escalation cohort, and dose escalation may be stopped early if emerging PK or safety data warrant it. Dose extension and treatment pauses are integrated, with a maximum extension of 35 cycles (≈24 months).

    Biological: STX-001

  • Experimental
    Phase 1 Combination (STX-001 with Pembrolizumab)

    A Phase 1, first-in-human (FIH), multiple ascending STX-001 dose administration, in combination with pembrolizumab, to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary antitumor activity in patients with advanced cancers. Consists of 4 planned dose escalation cohorts (Cohorts 1c) of STX-001and pembrolizumab given concurrently, with new patients enrolled in each dose escalation cohort. Dose escalation may be halted early if PK or safety data indicate, and the dose extension period extends up to 35 cycles with treatment pauses. Backfill enrollment is permitted up to 30 patients.

    Biological: STX-001 · Biological: Keytruda®

  • Experimental
    Phase 2 Combination (STX-001 with Pembrolizumab)

    Phase 2 consists of dose expansion cohorts in patients with 2 defined cancer types: triple negative breast cancer (TNBC) and melanoma. Phase 2 will evaluate STX-001 in combination with pembrolizumab; the recommended Phase 2 dose (RP2D) of STX-001 will be selected based on analysis of the totality of data from Phase 1 safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and preliminary efficacy data. Dose extension and treatment pauses are incorporated.

    Biological: STX-001 · Biological: Keytruda®

  • Experimental
    Phase 1 Visceral-lesion Monotherapy (Cohort 1Vm)

    Phase 1, first-in-human (FIH) monotherapy cohort targeting visceral lesions. STX-001 is administered intratumorally at 30 µg, 100 µg and 300 µg to evaluate safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary antitumor activity in patients with advanced cancers. Cohort 1Vm is part of the dose escalation stage; new patients are enrolled at each dose level, and backfill enrollment is permitted up to 30 patients. Dose escalation may be stopped early if PK or safety data warrant it.

  • Experimental
    Phase 2 Advanced-Melanoma Monotherapy

    Phase 2 dose expansion cohort evaluating STX-001 monotherapy administered intratumorally to patients with advanced melanoma. Assesses safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary antitumor activity with the recommended dose selected based on Phase 1 data. Dose extension and treatment pauses are allowed up to 35 cycles.

Interventions

  • BiologicalSTX-001

    STX-001 encapsulates a self-replicating RNA encoded for IL-12, contained within an LNP for intratumoral injection. Injections may be administered into multiple lesions according to protocol-defined procedures.

  • BiologicalPembrolizumabStudies of PembrolizumabPembrolizumab pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Pembrolizumab (Keytruda USPI 2023) is a marketed PD-1 blocking humanized monoclonal IgG4 kappa antibody.

    Also known as: Pembrolizumab

06

What researchers measure

Primary outcomes

  1. Number and nature of dose-limiting toxicities (DLTs), treatment-emergent adverse events (TEAEs) and serious adverse events (SAEs) in patients with advanced solid tumors.

    The occurrence of DLTs, TEAEs, and SAEs will be used to determine the maximum tolerated dose and recommended Phase 2 dose of STX-001.

    Time frame: From time of informed consent until 30 days after the last dose of investigational product (STX-001).

  2. Occurrence of changes from baseline in patients' clinical safety laboratory values and vital signs to assess the safety and tolerability of STX-001.

    Collection and analysis of changes in data from baseline of patients' vital signs (temperature, pulse, respiratory rate, blood pressure, oxygen saturation via pulse oximetry) as well as clinical safety laboratory values (chemistry, hematology, coagulation, complement (Bb \& C3a), urinalysis, and lipids).

    Time frame: From time of informed consent until 30 days after the last dose of investigational product (STX-001).

Secondary outcomes

  1. Assessment of PK in patients dosed with STX-001

    Individual and mean plasma STX-001 concentrations versus time data will be collected, summarized, and plotted by dose level.

    Time frame: From time of informed consent until 30 days after the last dose of investigational product (STX-001).

  2. Assessment of Tumor infiltrating lymphocytes (TILs)

    Assessment of STX-001 PK concentrations in mono therapy and safety and tolerability of STX-001 in combination with pembrolizumab in the tumor microenvironment (biopsy).

    Time frame: From time of informed consent until 30 days after the last dose of investigational product (STX-001).

  3. Number and nature of preliminary antitumor activity of STX-001.

    Proportion of patients with objective response rate (ORR), complete response (CR), or partial response (PR) per RECIST 1.1.

    Time frame: From time of informed consent until 30 days after the last dose of investigational product (STX-001).

  4. Number and nature of preliminary antitumor activity of STX-001 in combination with pembrolizumab.

    Proportion of patients with objective response rate (ORR), disease control rate (DCR), complete response (CR), partial response (PR) or stable disease (SD) per RECIST 1.1.

    Time frame: From time of informed consent until 30 days after the last dose of investigational product (STX-001).

  5. Number and nature of preliminary antitumor activity of STX-001.

    Proportion of patients with progression-free survival (PFS), defined as the time from randomization to first evidence of radiographically detectable disease or death from any cause. Proportion of patients with duration of response (DOR) (CR or PR), per RECIST 1.1.

    Time frame: From time of informed consent until 18 months after the last dose of investigational product (STX-001).

  6. Number and nature of preliminary antitumor activity of STX-001 in combination with pembrolizumab.

    Proportion of patients with progression-free survival (PFS), defined as the time from randomization to first evidence of radiographically detectable disease or death from any cause. Proportion of patients with overall survival (OS, duration of response (DOR) (CR or PR), per RECIST 1.1.

    Time frame: From time of informed consent until 18 months after the last dose of investigational product (STX-001).

  7. Occurrence of TEAEs, SAEs, and AESIs graded according to NCI CTCAE v5.0

    Assessment of the safety and tolerability of STX-001 in patients with advanced solid tumors.

    Time frame: From time of informed consent until 30 days after the last dose of investigational product (STX-001).

  8. Occurrence of changes from baseline in patients' clinical safety laboratory values and vital signs to assess the safety and tolerability of STX-001.in combination with pembrolizumab.

    Collection and analysis of changes in data from baseline of patients' vital signs (temperature, pulse, respiratory rate, blood pressure, oxygen saturation via pulse oximetry) as well as clinical safety laboratory values (chemistry, hematology, coagulation, complement (Bb \& C3a), urinalysis, and lipids).

    Time frame: From time of informed consent until 30 days after the last dose of investigational product (STX-001).

  9. Objective Response Rate (ORR) in patients with advanced solid tumors.

    Objective Response Rate (ORR) is defined as the proportion of patients with confirmed response (CR) or confirmed partial response (PR).

    Time frame: From time of informed consent until 30 days after the last dose of investigational product (STX-001).

07

Study locations

7 sites
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Ran from May 2024 to primary completion in Jun 2026, 25 months.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 19, 2026: primary completion May 2027 → Jun 2026 and completion Nov 2028 → Jun 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Feb 2, 2024
First posted
Feb 8, 2024
StartActual
May 3, 2024
Primary completionActual
Jun 17, 2026was May 2027
CompletionActual
Jun 17, 2026was Nov 2028
Last update
Nov 19, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Completed
changed Nov 19, 2026
Primary completion
May 2027→Jun 17, 2026 (actual)
Nov 19, 2026
Study completion
Nov 2028→Jun 17, 2026 (actual)
Nov 19, 2026
Enrollment
108 (estimated)→39 (actual)
Nov 19, 2026
Show all 1 update
  1. Nov 19, 2026
    Recruiting→Completed
    Primary completion May 2027→Jun 17, 2026 (now actual)
    Study completion Nov 2028→Jun 17, 2026 (now actual)
    Enrollment 108 (estimated)→39 (actual)
    + 4 other changes: verification date, arm descriptions, contact details and site details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06249048
Lead sponsor
Strand Therapeutics Inc.
Responsible party
Sponsor
First posted
Feb 8, 2024
Start date
May 3, 2024
Primary completion
Jun 17, 2026
Completion
Jun 17, 2026
Last update
Nov 19, 2026

Study contacts

Jason Luke, MD
study chair · Strand Therapeutics

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion